Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Global PharmaPartners
Springfield, Missouri, United States
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Global PharmaPartners primarily operates as a consulting and licensing partner for pharma/biotech CDMOs with a focus on generics, specialty drugs, and advanced peptides (e.g., GLP-1 analogues). They are associated with deals for late-stage/Phase 3 assets (e.g., Cingulate's CTx-1301 in Phase 3 for ADHD and APT3712, an advanced GLP-1 analogue for obesity and diabetes). No in-house clinical assets; their role centers on partnering and licensing support.[5][7]
- Therapeutic areas
- EndocrinologyPsychiatry
- Modalities
- Small moleculePeptides
- Industry
- Consulting
02
Partnerships
AmpeptecMurli Krishna PharmaAMI LifesciencesCingulate
Beyond the preview
Go deeper on Global PharmaPartners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Global PharmaPartners.